The news of a planned FDA submission for a new treatment typically generates positive sentiment among investors, as it indicates progress in the company's pipeline. The anticipation of a new product launch can lead to increased investor interest and potentially a higher stock price in the short term. However, the actual impact will depend on the market's perception of the treatment's potential success and the competitive landscape.